Mereo BioPharma Group plc PDMR Notification (8185B)

TIDMMPH

RNS Number : 8185B

Mereo BioPharma Group plc

12 October 2020

Mereo BioPharma Group plc

PDMR Notification

London and Redwood City, Calif ., October 12, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 09, 2020, Charles Sermon, General Counsel at Mereo, purchased 18,405 American Depositary Shares (ADSs) at a price of USD 2.41 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

 
 1    Details of the person discharging managerial responsibilities 
 a)   Name                      Charles Sermon 
     ------------------------  -------------------------------------------------- 
 2    Reason for the notification 
     ---------------------------------------------------------------------------- 
 a)   Position/status           General Counsel 
     ------------------------  -------------------------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
     ------------------------  -------------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------------- 
 a)   Name                      Mereo BioPharma Group plc 
     ------------------------  -------------------------------------------------- 
 b)   LEI                       213800U8JQHIJOS5AS09 
     ------------------------  -------------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ---------------------------------------------------------------------------- 
 a)   Description of            AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 
       the financial             5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES 
       instrument, type          OF GBP0.003 EACH 
       of instrument 
       and identification 
       code 
     ------------------------  -------------------------------------------------- 
 b)   Nature of the             PURCHASE 
       transaction 
     ------------------------  -------------------------------------------------- 
 c)   Price(s) and                Price(s)    Volume(s) 
       volume(s)                   USD 2.41    18,405 
                                              ---------- 
     ------------------------  -------------------------------------------------- 
 d)   Aggregated information: 
       volume, Price 
     ------------------------  -------------------------------------------------- 
 e)   Date of the transaction   2020-10-09 
     ------------------------  -------------------------------------------------- 
 f)   Place of the              XNMS (Nasdaq Global Market) 
       transaction 
     ------------------------  -------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBDBDGBSBDGGD

(END) Dow Jones Newswires

October 12, 2020 08:44 ET (12:44 GMT)